Microba Life Sciences (FRA:F3Y) Total Stockholders Equity: €14.87 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:F3Y Microba Life Sciences Ltd FRA:F3Y
29 GF Score
Price €0.03
GF Value €0.08
! 5 Warning Signs
View Full Analysis

What is Microba Life Sciences Total Stockholders Equity?

Microba Life Sciences FRA:F3Y 29 Total Stockholders Equity is €14.87 Mil as of Jun. 2026. GuruFocus rates FRA:F3Y with a GF Score™ of 29/100 and a GF Value™ of €0.08. The stock has 5 warning signs investors should review.

Microba Life Sciences's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €14.87 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Microba Life Sciences's Book Value per Share for the quarter that ended in Jun. 2026 was €0.02. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Microba Life Sciences's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.17.


Microba Life Sciences  (FRA:F3Y) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Microba Life Sciences's Book Value per Share for the quarter that ended in Jun. 2026 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Microba Life Sciences's Debt-to-Equity for the quarter that ended in Jun. 2026 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Microba Life Sciences Total Stockholders Equity Related Terms


Microba Life Sciences Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Microba Life Sciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microba Life Sciences Total Stockholders Equity Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23 Jun24 Jun25 Jun26
Total Stockholders Equity
22.29 23.90 25.43 18.34 14.87

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.43 21.58 18.34 17.13 14.87
FRA:F3Y
29GF Score
Microba Life Sciences Ltd FRA:F3Y
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €14.87 Mil mean?
Microba Life Sciences (FRA:F3Y) has a Total Stockholders Equity of €14.87 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Microba Life Sciences and its competitors.
Is Microba Life Sciences' Total Stockholders Equity too high?
Microba Life Sciences' current Total Stockholders Equity is €14.87 Mil. Overall, Microba Life Sciences has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Microba Life Sciences' Total Stockholders Equity compare to TMO and DHR?
Microba Life Sciences' Total Stockholders Equity of €14.87 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Diagnostics & Research company?
A good Total Stockholders Equity depends on the Medical Diagnostics & Research industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Microba Life Sciences and its competitors. Microba Life Sciences's current Total Stockholders Equity is €14.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Microba Life Sciences (FRA:F3Y) has a current Total Stockholders Equity of €14.87 Mil. The stock's GF Value™ is €0.08, compared to a current price of €0.03 — trading 63.1% below its estimated fair value. The current Total Stockholders Equity is €14.87 Mil. Microba Life Sciences' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Microba Life Sciences (FRA:F3Y), the current Total Stockholders Equity is €14.87 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Microba Life Sciences (FRA:F3Y) Overvalued in 2026?

Based on GuruFocus' analysis, Microba Life Sciences stock appears to be undervalued. The current stock price of €0.03 is trading 63.1% below its estimated GF Value™ of €0.08.

Key valuation signals for FRA:F3Y:

  • Total Stockholders Equity: €14.87 Mil
  • GF Value™: €0.08 vs. price of €0.03 (63.1% below fair value)
  • GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the FRA:F3Y stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Microba Life Sciences Business Description

Other Exchanges MAP:Australia
Address 324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
29GF Score

Get the complete analysis for FRA:F3Y

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price
€0.08
GF Value